Producer
Boehringer Ingelheim Animal Health
Global leader in Marek's disease vaccine production and the world's largest producer of poultry vaccines. Its Gainesville, Georgia facility produces approximately 60 billion poultry vaccine doses per year for the US and ~60 other countries — one of the largest single biological manufacturing sites in the world. In 2024, acquired Elanco's US poultry biologics portfolio for $885M, further consolidating leadership. Product portfolio includes HVT-based vaccines, PREVEXXION RN (chimeric Serotype 1, first new MDV1 innovation in 40+ years, approved EU/UK 2021), and the VAXXITEK recombinant HVT vector family. Also a major human pharmaceutical company (Jardiance, Pradaxa, Spiriva, Dupixent collaborator).
2
Inputs supplied
2
Goods downstream
4
Facilities
0
Stories
What they make
2 inputs Boehringer Ingelheim Animal Health supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Boehringer Ingelheim Animal Health makes, pick one to see the full supply chain.
Where they make it
4 facilities
Boehringer Ingelheim - Jonage (Lyon), France →
FR200M+ EUR investment; one of Europes largest biotech vaccine sites; antigen and vaccine manufacturing; critical for Ingelvac PRRS MLV production
Boehringer Ingelheim - St. Joseph, Missouri →
US100+ years of operations; $80M+ expansion; historic US swine vaccine manufacturing hub
Boehringer Ingelheim - Taizhou, Jiangsu China →
CN58M EUR investment; 125M dose/yr capacity; partnership with China Medical City; first local Ingelvac PRRS MLV production; Asias leading vaccine facility
Boehringer Ingelheim Animal Health Gainesville Facility →
USGainesville, Hall County, Georgia · pharmaceutical_plant
World's largest single-site poultry vaccine manufacturing facility; produces approximately 60 billion doses per year for the US and ~60 other countries. First BI Animal Health US site to be certified carbon neutral (2022). Produces HVT-based monovalents, bivalents, recombinant HVT vector vaccines (VAXXITEK), and PREVEXXION RN. 60 billion doses/year from one facility represents an extraordinary concentration — an event (natural disaster, pandemic shutdown, fire, contamination) at this single Georgia location would immediately affect global MDV vaccine supply for both the US and 60 export countries.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
Poultry Biologics & Vaccines
28%Swine & Livestock Biologics
22%Animal Parasiticides
20%Human Pharmaceuticals
30%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2021
In 2024, Boehringer Ingelheim acquired Elanco Animal Health's entire US poultry biologics portfolio for $885 million — gaining not only Elanco's MDV vaccine products and the former Lohmann Animal Health manufacturing capabilities, but also effectively removing Elanco as a significant MDV competitor in the US market. BI is now simultaneously the world's largest MDV vaccine producer, the acquirer of its third-largest US competitor's poultry biologics business, and the developer of PREVEXXION RN — the first new MDV Serotype 1 vaccine innovation in 40+ years. A single company controls both the dominant market position and the next-generation vaccine pipeline for the only known case of vaccine-driven pathogen evolution.
Boehringer Ingelheim ↗Origin2023
Boehringer Ingelheim entered animal health in the 1960s alongside its established human pharmaceuticals business, initially through Boehringer Ingelheim Vetmedica. The company built a dominant position in poultry biologics through sustained investment in its Gainesville, Georgia vaccine manufacturing site — which grew to produce approximately 60 billion poultry vaccine doses per year, making it one of the largest biological manufacturing facilities on earth. The 2024 acquisition of Elanco's poultry biologics portfolio for $885 million further consolidated BI's control over Marek's disease vaccines specifically.
Boehringer Ingelheim ↗